Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2012 Apr 15.

Published in final edited form as: J Acquir Immune Defic Syndr. 2011 Apr 15;56(5):412–419. doi: 10.1097/QAI.0b013e31820fd093

Table 2. Atazanavir without tenofovir subjects: Median (interquartile range) atazanavir and ritonavir non-compartmental pharmacokinetic parameters.

		Second Trimester n=1	Third Trimester n=18	Postpartum n=13
Atazanavir	AUC_0-24 (mcg*hr/mL)	88.2	41.9 (27.4 – 60.8)^*	57.9 (47.1 – 64.8)
	C_pre-dose (mcg/mL)	3.6	0.8 (0.35 – 1.1)^*	1.7 (1.3 – 2.5)
	C_max (mcg/mL)	9.1	3.6 (2.8 – 5.1)	4.1 (3 – 5.8)
	T_max (hr)	4	4 (2.5 – 4)	2 (1 – 4)
	C_24h (mcg/mL)	2.0	0.7 (0.5 – 1.1)^*	1.2 (1.1 – 2)
	C_min (mcg/mL)	2.0	0.7 (0.4 – 0.9)^*	1.2 (1.1 – 1.8)
	CL/F (L/hr)	3.4	7.2 (4.9 – 11)^*	5.2 (4.6 – 6.4)
	V_d/F (L)	119	112 (92 – 151)	153 (102 – 167)
	t½ (hr)	24.3	10.9 (8.6 – 12.8)^*	15.3 (12 – 22)
Ritonavir	Absorption Lag, n (%)	1 (100%)	7 (39%)	3 (23%)
	AUC_0-24 (mcg*hr/mL)	14.7	5.7 (4.1 – 7.9)^*	13.1 (10.8 – 17)
	C_pre-dose (mcg/mL)	0.6	<0.094 (<0.094 – <0.094)^*	0.2 (<0.094 – 0.3)
	C_max (mcg/mL)	2.0	0.8 (0.6 – 0.9)^*	1.8 (1.1 – 2.3)
	T_max (hr)	6	4 (2 – 6)	4 (2 – 6)
	C_24h (mcg/mL)	<0.094	<0.094 (<0.094 – <0.094)^*	<0.094 (<0.094 – 0.1)
	C_min (mcg/mL)	<0.094	<0.094 (<0.094– <0.094)^*	<0.094 (<0.094– 0.1)
	CL/F (L/hr)	6.8	17.6 (12.6 – 24.6)^*	7.7 (5.9 – 9.3)
	V_d/F (L)	34.2	110 (82 – 146)^*	47 (40 – 71)
	t½ (hr)	3.5	4.8 (3.8 – 5.8)	5.0 (3.3 – 5.8)

^*

p<0.05, third trimester compared to postpartum;

AUC_0-24 = area under the plasma concentration-time curve;

C_pre-dose = pre-dose concentration;

C_max = maximum concentration;

T_max = time post-dose of maximum concentration;

C_24h = 24-hour post-dose concentration;

C_min = minimum concentration;

T_min = time post-dose of minimum concentration;

CL/F = oral clearance;

V_d/F = apparent volume of distribution;

t½ = half-life